公开(公告)号：US10213433B2

公开(公告)日：2019-02-26

申请号：US14537392

申请日：2014-11-10

Applicant: AbbVie Inc.

Inventor： Nathaniel Catron ,  David Lindley ,  Jonathan M. Miller ,  Eric A. Schmitt ,  Ping Tong

IPC: A61K31/397 ,  A61K31/5377 ,  A61K9/14 ,  A61K9/16 ,  A61K9/48 ,  A61K31/437 ,  A61K31/496

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

公开(公告)号：US20190275051A1

公开(公告)日：2019-09-12

申请号：US16239199

申请日：2019-01-03

Applicant: AbbVie Inc.

Inventor： Nathaniel Catron ,  David Lindley ,  Jonathan M. Miller ,  Eric A. Schmitt ,  Ping Tong

IPC: A61K31/5377 ,  A61K9/48 ,  A61K31/496 ,  A61K31/437 ,  A61K9/14 ,  A61K9/16

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

公开(公告)号：US20250161318A1

公开(公告)日：2025-05-22

申请号：US18809439

申请日：2024-08-20

Applicant: AbbVie Inc.

Inventor： Nathaniel Catron ,  David Lindley ,  Jonathan M. Miller ,  Eric A. Schmitt ,  Ping Tong

IPC: A61K31/5377 ,  A61K9/14 ,  A61K9/16 ,  A61K9/48 ,  A61K31/437 ,  A61K31/496

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

公开(公告)号：US20220125796A1

公开(公告)日：2022-04-28

申请号：US17341158

申请日：2021-06-07

Applicant: AbbVie Inc.

Inventor： Nathaniel Catron ,  David Lindley ,  Jonathan M. Miller ,  Eric A. Schmitt ,  Ping Tong

IPC: A61K31/5377 ,  A61K9/16 ,  A61K9/14 ,  A61K31/496 ,  A61K31/437 ,  A61K9/48

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

公开(公告)号：US20150157639A1

公开(公告)日：2015-06-11

申请号：US14537392

申请日：2014-11-10

Applicant: AbbVie Inc.

Inventor： Nathaniel Catron ,  David Lindley ,  Jonathan M. Miller ,  Eric A. Schmitt ,  Ping Tong

IPC: A61K31/5377 ,  A61K31/496

CPC classification number: A61K31/5377 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/4866 ,  A61K31/437 ,  A61K31/496 ,  Y02A50/411

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract translation: 促凋亡固体分散体以基本上非结晶形式包含分散在固体基质中的如本文定义的式I的Bcl-2家族蛋白质抑制化合物，其包含（a）药学上可接受的水溶性聚合物载体和（ b）药学上可接受的表面活性剂。 制备这种固体分散体的方法包括将化合物，聚合物载体和表面活性剂溶解在合适的溶剂中，并除去溶剂以提供包含聚合物载体和表面活性剂的固体基质，并使化合物分散在基本上不结晶 形成。 该固体分散体适合于需要其的受试者口服给药以治疗以一种或多种抗凋亡Bcl-2家族蛋白（例如癌症）过表达为特征的疾病。